These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25674175)

  • 21. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
    Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature.
    Chrousos GP; Harris AG
    Neuroimmunomodulation; 1998; 5(6):288-308. PubMed ID: 9762011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review.
    Richy F; Bousquet J; Ehrlich GE; Meunier PJ; Israel E; Morii H; Devogelaer JP; Peel N; Haim M; Bruyere O; Reginster JY
    Osteoporos Int; 2003 May; 14(3):179-90. PubMed ID: 12730758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic side effects of inhaled corticosteroids in patients with asthma.
    Dahl R
    Respir Med; 2006 Aug; 100(8):1307-17. PubMed ID: 16412623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
    Ducharme FM; Lasserson TJ; Cates CJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003137. PubMed ID: 17054161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The properties of inhaled corticosteroids: similarities and differences.
    Barnes NC
    Prim Care Respir J; 2007 Jun; 16(3):149-54. PubMed ID: 17530144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
    Ram FS; Cates CJ; Ducharme FM
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003137. PubMed ID: 15674901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of study design on the evaluation of inhaled and intranasal corticosteroids' effect on hypothalamic-pituitary-adrenal axis function, part I: general overview of HPA axis study design.
    Fan Y; Ma L; Pippins J; Limb S; Xu Y; Sahajwalla CG
    J Pharm Sci; 2013 Oct; 102(10):3513-27. PubMed ID: 23918409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of inhaled steroids on growth, bone metabolism, and adrenal function.
    Allen DB
    Adv Pediatr; 2006; 53():101-10. PubMed ID: 17089864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled corticosteroids, bone mineral density and fracture in older people.
    Hubbard R; Tattersfield A
    Drugs Aging; 2004; 21(10):631-8. PubMed ID: 15287822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
    Chauhan BF; Chartrand C; Ducharme FM
    Cochrane Database Syst Rev; 2013 Feb; (2):CD009611. PubMed ID: 23450606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids.
    Bernstein DI; Allen DB
    Ann Allergy Asthma Immunol; 2007 Feb; 98(2):118-27. PubMed ID: 17304877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
    Burge S
    Drugs; 2001; 61(11):1535-44. PubMed ID: 11577791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults.
    Ni CM; Greenstone IR; Ducharme FM
    Cochrane Database Syst Rev; 2005 Apr; (2):CD005307. PubMed ID: 15846751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciclesonide: a closer look at its systemic and oropharyngeal safety profile.
    Berger WE
    Curr Drug Saf; 2006 Aug; 1(3):265-70. PubMed ID: 18690937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled corticosteroids: Ocular safety and the hypothalamic-pituitary-adrenal axis.
    Carr WW; Szefler SJ
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):589-594. PubMed ID: 27979014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishing a therapeutic index for the inhaled corticosteroids: part II. Comparisons of systemic activity and safety among different inhaled corticosteroids.
    Sorkness CA
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 2):S52-64. PubMed ID: 9798723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations.
    Chiang PC; Hu Y; Blom JD; Thompson DC
    Nanoscale Res Lett; 2010 Apr; 5(6):1010-9. PubMed ID: 20672144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.
    Chalmers JD; Tebboth A; Gayle A; Ternouth A; Ramscar N
    NPJ Prim Care Respir Med; 2017 Jun; 27(1):43. PubMed ID: 28663549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.